[Federal Register Volume 64, Number 137 (Monday, July 19, 1999)]
[Notices]
[Page 38678]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-18375]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the US
Government and is available for licensing in the US in accordance with
35 U.S.C. 207 to achieve expeditious commercialization of results of
federally-funded research and development. Foreign patent applications
are filed on selected inventions to extend market coverage for
companies and may also be available for licensing.
ADDRESSES: Licensing information and a copy of the U.S. patent
application listed below may be obtained by contacting Susan S. Rucker,
J.D., at the Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804; telephone: 301/496-7056 ext. 245; fax: 301/402-0220; e-
mail:sr156v@nih.gov. A signed Confidential Disclosure Agreement will be
required to receive a copy of the patent application.
Immunoadhesins and Methods of Production Thereof
KG Csaky, E Anglade, DM Sullivan (all of NEI), WJ Larochelle (NCI)
Serial No. 08/814,567 filed 10 Mar 97
This patent application relates to the field of immunoadhesins.
Immunoadhesins, also known as immunoligands, Ig- or Fc- fusion proteins
or chimeras are chimeric molecules comprised of a non-immunoglobulin
binding region (e.g., cell surface receptor, ligand, cell adhesion
molecule) and an antibody constant domain. Such molecules can be used
to identify receptors or ligands, in structure-function studies or as
therapeutic agents.
In particular, the application describes a method for producing
immunoadhesins which utilizes a replication-deficient adenoviral
expression system. This system addresses some of the defects of other
immunoadhesion production systems utilizing transfection of plasmid DNA
in either a transient or stable system by providing efficient, high
level gene expression, appropriate assembly/post-translation
modification and ease of purification. Particular immunoadhesins which
have been produced using this system are incorporate IL-10, IL-2, IL-
13, IL2ra, IL-1ra, mutant IL-4, ICAM, TGF-11, or TGF-
1223,225 as the non-immunoglobulin portion.
This research has been published, in part, in Anglade, et al.
``Interleukin-10 immunoadhesin production by a replication-defective
adenovirus'' J. Immunol. Methods 202(1): 41-8 (March 10, 1997).
Dated: July 13, 1999.
Jack Spiegel, Ph.D.,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 99-18375 Filed 7-16-99; 8:45 am]
BILLING CODE 4140-01-M
